More rare disease drugs must also be approved, says EURORDIS.
NHS will not fund Kanuma for rare disease LAL-D.
Company says it will listen to concerns of patient advocates
Watchdog accused of ignoring stakeholder consensus and call for negotiations
Biotech’s R&D operations will be spun off.
Price of epilepsy drug increased 85,000% since 2001, says FTC.
Takeda makes epilepsy deal as GW prepares for US filing.
California’s Kite strikes deals with Fosun and Daiichi Sankyo.